Skip to content
PhoreMost Ltd logo — Drugging the Undruggable®

PhoreMost Ltd

Drugging the Undruggable®

Founded 2014 United Kingdom United Kingdom 33 employees Series B Total: $77.22M Biopharma, Biotechnology +2

General Information

Company Name PhoreMost Ltd
Founded Year 2014
Location United Kingdom United Kingdom
Employees 33
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series B
Business Model B2B, Platform, B2B2B
Revenue Model Licensing, Project Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with PhoreMost Ltd. To contact PhoreMost Ltd, visit phoremost.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PhoreMost Ltd compare?

A PDF of PhoreMost Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PhoreMost Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PhoreMost Ltd

PhoreMost Ltd, founded in 2014, is a biopharmaceutical and biotechnology innovator located in Cambridge, UK. With the ambitious slogan, "Drugging the Undruggable®", the company leverages its proprietary technology, SITESEEKER®, along with PROTEINi® libraries to identify and target novel drug possibilities. This approach aims to address challenging disease areas, such as cancer, by expanding the 'druggable' landscape, potentially increasing therapeutic diversity and affordability.

The company focuses on creating a pipeline of breakthrough drug discovery programs, collaborating with academic and industrial partners worldwide to enhance drug discovery's speed and effectiveness. PhoreMost has established PhoreAll and PhorEST initiatives to promote inclusivity and sustainability.

In a significant growth phase, PhoreMost secured a $12.00M Series B investment on 12 September 2024. Notable investors include Parkwalk Advisors, Amadeus Capital Partners, Astellas Venture Management, Jonathan Milner, and Business Growth Fund.

Business keywords: Drug Discovery, Undruggable Targets, SITESEEKER Technology, PROTEINi Libraries, Novel Therapeutics, Cancer Therapies, Unmet Medical Needs, Targeted Therapies, Academic Collaboration, Industrial Collaboration, Biotechnology Innovation, Platform Technology Development, Cost-Efficient Drug Development, Inclusion Initiatives, Green Initiatives

Services & Products

development of cancer therapies
scientific research
drug discovery

Target Customers

cancer patients healthcare providers pharmaceutical companies research institutions

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $11.79M 4
Parkwalk Advisors, Amadeus Capital Partners +2
01 Sep 2024
Series B $46.00M 8
Parkwalk Advisors, Astellas Venture Management +6
01 Mar 2021
Series A $15.00M 5
Parkwalk Advisors, Amadeus Capital Partners +3
01 May 2018
Grant £630.00K -
01 Jan 2017
Seed $3.80M 5
Parkwalk Advisors, Amadeus Capital Partners +3
01 Mar 2015
Spinout Undisclosed 1
The University of Cambridge
01 Jan 2014

PhoreMost Ltd Alternatives & Competitors

View All Alternatives
PhoreMost Ltd vs
FogPharma
FogPharma United States

Until everything is druggable.

Series E
146 employees
Biopharma, Biotechnology
PhoreMost Ltd vs

Developing next-generation targeted cancer immunotherapy treatments

Series B
50 employees
Biopharma, Health Care
PhoreMost Ltd vs

A precision oncology company focused on small molecule therapies optimized to target key driver mech...

Series A
52 employees
Biotechnology, Health Care

FAQ About PhoreMost Ltd

Drugging the Undruggable®
PhoreMost Ltd was founded in 2014.
PhoreMost Ltd is headquartered in United Kingdom.
PhoreMost Ltd operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Drug Discovery, Undruggable Targets, SITESEEKER Technology and PROTEINi Libraries. Its customers include cancer patients, healthcare providers and pharmaceutical companies.
PhoreMost Ltd has a B2B, Platform and B2B2B business model. Its revenue comes from Licensing, Project Based and Service Fee.
PhoreMost Ltd has approximately 33 employees.
PhoreMost Ltd has completed 6 funding rounds, raising a total of $77.22M. The latest funding stage is Series B.
PhoreMost Ltd offers: development of cancer therapies, scientific research, drug discovery.
Top alternatives and competitors to PhoreMost Ltd include FogPharma, iOmx Therapeutics AG, Synnovation Therapeutics, Abdera Therapeutics, Oxford BioTherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PhoreMost Ltd and FogPharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PhoreMost Ltd, https://bouncewatch.com/company/phoremost-ltd, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout